Rigor Reviewed

Rigor-Reviewed Manuscript

Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.

Name: Αlpha¹ Rigor Record — Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.
Item: Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.
Rating: 96
Author: Αlpha¹

Hou J, Lim SG, Buti M, Yuen MF, Gane E, Lampertico P, Terrault N, Nguyen H, Yim HJ, Xie Q, Lin J, Qiu Y, Jeng WJ, Heo J, Peng CY, Chen CH, Chuang WL, Xie Y, Hlebowicz M, Idriz N, Mehta R, Agarwal K, Gomes da Silva MM, Franca A, Cernat R, Leerapun A, Coffin CS, Gadano A, Andreone P, Fujiyama S, Sevastianos V, Suzuki Y, Ratziu V, Riachi G, Stocker H, Lim TH, Asselah T, Tanaka Y, Holmes J, Liang X, Cremer J, Lukić T, Plein H, Quinn G, Tao Y, Paff M, Theodore D, Elston R, B-Well Study Group

Paper source

Read full text

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.25★ (Adequate), 0 critical, 2 high issues for “Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No data or code availability links were detected to verify.

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted pair of replicate phase 3 randomized trials with strong methodology, clear reporting of demographics, ethics, and statistical methods. The main weakness is the vague data sharing statement, which lacks specific access details. Minor copyedit issues and a small N discrepancy in Table 1 are noted.

Both reviewers classified the study as interventional, and no divergence was noted. The evaluation covered the full text, including methods, results, and discussion. Bench-specific criteria (e.g., cell line authentication) were not applicable. The statistics verification checked only 2 tests, so the broader statistical correctness is not fully verified.

4 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites prior research on HBV infection, functional cure definitions, and phase 2 bepirovirsen studies. The rationale for the trials is clearly linked to the need for finite therapies achieving functional cure. Limitations of prior research are implicitly addressed by the replicate trial design and the focus on a defined endpoint.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a clear scientific premise with prior work and a logical rationale for the trials.

Evidence

paraphrase[Introduction, paragraph 1-3]

“Extended follow-up of the phase 2 bepirovirsen studies showed that some patients with a baseline HBsAg level of 3000 IU per milliliter or less who received a course of bepirovirsen were able to discontinue NA therapy and have a durable functional cure.”

paraphrase[Introduction, paragraph 3]

“In these trials, we assessed the percentage of patients who had a functional cure with 24 weeks of bepirovirsen therapy, as compared with placebo.”

paraphrase[Discussion, paragraph 2]

“The replicate trial design and multicountry enrollment across B-Well 1 and B-Well 2 provide robust evidence for the efficacy and safety of bepirovirsen in patients with chronic HBV infection worldwide.”

PASSReviewer 2· 95% conf

The paper establishes a clear scientific premise with prior work and a logical rationale for the trials.

Evidence

paraphrase[Introduction, paragraph 2]

paraphrase[Introduction, paragraph 3]

“In these trials, we assessed the percentage of patients who had a functional cure with 24 weeks of bepirovirsen therapy, as compared with placebo.”

paraphrase[Discussion, paragraph 2]

Randomization was performed via a central interactive response system with stratification by HBsAg level. The trials were double-blind. A power analysis is reported (≥750 patients per trial for >99% power). Inclusion/exclusion criteria are described. Missing data handling is specified (nonresponse imputation). The comparator is placebo, and the replicate design provides independent replication.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trials are well-designed with adequate randomization, blinding, power analysis, and inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomization and Treatment]

“The patients were randomly assigned in a 2:1 ratio to receive bepirovirsen or placebo through a central interactive response system, with stratification according to the screening HBsAg level.”

paraphrase[Methods, Trial Design and Oversight]

“patients were recruited in the double-blind, placebo-controlled B-Well 1 and B-Well 2 trials”

direct quote[Methods, Statistical Analysis]

“We determined that the enrollment of at least 750 patients in each of the B-Well trials would provide the trial with more than 99% power to determine the primary outcome with a two-sided alpha level of 0.05.”